Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Impact of a novel mutation in the 5′-flanking region of natriuretic peptide precursor B gene on the antihypertensive effects of sodium nitroprusside in patients with hypertension

Journal of Human Hypertension volume 27, pages 271–276 (2013)Cite this article

Subjects

Abstract

Our aim was to identify the possible mutations of the natriuretic peptide precursor B (NPPB) gene in a family with hereditary hypertension, and determine whether the mutations are associated with the antihypertensive effect of sodium nitroprusside. The subjects included one family with hereditary hypertension, 36 cases of sporadic hypertension and 120 healthy controls. The 5′-flanking sequence of NPPB was amplified with PCR, and the presence of mutations was analyzed by direct sequencing. Patients with hypertension were treated with sodium nitroprusside and blood pressure data and serum B-type natriuretic peptide (BNP) levels were measured. A novel complex mutation in 5′-flanking sequence of the NPPB gene was detected in three patients (II 2, III 2, and III 5) of the hypertension family, which included c.-1195_ -1176 insert 5′-CCTTCTTTCTTTCTTTCTTT-3′, c.-1208 T>A, c.-1214 T>C, and c.-1216 T>A. Patients with this mutation were less sensitive to sodium nitroprusside treatment. Sporadic hypertension patients (without NPPB gene mutation) and patients with the c.-1181 T>A point mutation were sensitive to sodium nitroprusside treatment. BNP levels of patients with the complex mutation were significantly lower than that of sporadic hypertension patients and c.-1181 T>A mutation patients before and during the early stage of sodium nitroprusside treatment. The complex mutation of the NPPB gene might be an etiological factor of hereditary malignant hypertension, and it is associated with low sensitivity to the antihypertensive effect of sodium nitroprusside.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Filigheddu F, Troffa C, Glorioso N . Pharmacogenomics of essential hypertension: are we going the right way. Cardiovasc Hematol Agents Med Chem 2006; 4: 7–15.

    Article  CAS  Google Scholar 

  2. Arnett DK, Claas SA, Glasser SP . Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006; 44: 107–118.

    Article  CAS  Google Scholar 

  3. Jones DS, Perlis RH . Pharmacogenetics, race, and psychiatry prospects and challenges. Harv Rev Psychiatry 2006; 14: 92–108.

    Article  Google Scholar 

  4. Schelleman H, St ricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM et al. Drug gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64: 801–816.

    Article  Google Scholar 

  5. Nakagawa K, Ishizaki T . Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther 2000; 86: 1–28.

    Article  CAS  Google Scholar 

  6. Harrison M, Maresso K, Broeckel U . Genetic determinants of hypertension: An update. Curr Hypertens Rep 2008; 10: 488–495.

    Article  CAS  Google Scholar 

  7. Levin ER, Gardner DG, Samson WK . Natriuretic peptides. N Engl J Med 1998; 339: 321–328.

    Article  CAS  Google Scholar 

  8. Kosuge K, Soma M, Nakayama T, Aoi N, Sato M, Izumi Y et al. A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5′-flanking region is associated with essential hypertension among Japanese females. Int J Med Sci 2007; 4: 146–152.

    Article  CAS  Google Scholar 

  9. Nakao K, Ogawa Y, Suga S, Imura H . Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens 1992; 10: 907–912.

    CAS  PubMed  Google Scholar 

  10. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710–1718.

    Article  CAS  Google Scholar 

  11. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009; 54: 1599–1606.

    Article  CAS  Google Scholar 

  12. Maisel AS . Cardiovascular and renal surrogate markers in the clinical management of hypertension. Cardiovasc Drugs Ther 2009; 23: 317–326.

    Article  CAS  Google Scholar 

  13. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R . N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666–675.

    Article  CAS  Google Scholar 

  14. de lemos JA, Morrow DA . Brain natriuretic peptide measurement in actue coronary syndrome: ready for clinical application. Circulation 2002; 106: 2868–2870.

    Article  Google Scholar 

  15. Lammers AE, Hislop AA, Haworth SG . Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135: 21–26.

    Article  Google Scholar 

  16. Ang DS, Wei L, Kao MP, Lang CC, Struthers AD . A comparison between B-type natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification. Heart 2009; 95: 1836–1842.

    Article  CAS  Google Scholar 

  17. Chen M, Chen X, Guo Y, Shi R, Zhang G . Brain natriuretic peptide rs198388 polymorphism and essential hypertension in Hunan Han people. J Cent South Univ (Med Sci) 2010; 35: 1207–1213.

    CAS  Google Scholar 

  18. Ogawa Y, Itoh H, Nakagawa O, Shirakami G, Tamura N, Yoshimasa T et al. Characterization of the 5′-flanking region and chromosomal assignment of the human brain natriuretic peptide gene. J Mol Med 1995; 73: 457–463.

    Article  CAS  Google Scholar 

  19. Szabó G, Molvarec A, Stenczer B, Rigó J, Nagy B . Natriuretic peptide precursor B gene (TTTC)(n) microsatellite polymorphism in pre-eclampsia. Clin Chim Acta 2011; 412: 1371–1375.

    Article  Google Scholar 

  20. Takeishi Y, Toriyama S, Takabatake N, Shibata Y, Konta T, Emi M et al. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem Biophys Res Commun 2007; 362: 480–484.

    Article  CAS  Google Scholar 

  21. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009; 41: 348–353.

    Article  CAS  Google Scholar 

  22. Ellis KL, Newton-Cheh C, Wang TJ, Frampton CM, Doughty RN, Whalley GA et al. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol 2011; 50: 695–701.

    Article  CAS  Google Scholar 

  23. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL . Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 2007; 21: 55–62.

    Article  CAS  Google Scholar 

  24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  25. Kitiyakara C, Guzman NJ . Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 1998; 9: 133–142.

    CAS  PubMed  Google Scholar 

  26. Ohta Y, Tsuchihashi T, Ohya Y, Fujii K, Hirakata H, Abe I et al. Trends in the pathophysiological characteristics of malignant hypertension. Hypertens Res 2001; 24: 489–492.

    Article  CAS  Google Scholar 

  27. Vaziri ND . Malignant or accelerated hypertension. West J Med 1984; 140: 575–582.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Schubert R, Krien U, Wulfsen I, Schiemann D, Lehmann G, Ulfig N et al. Nitric oxide donor sodium nitroprusside dilates rat small arteries by activation of inward rectifier potassium channels. Hypertension 2004; 43: 891–896.

    Article  CAS  Google Scholar 

  29. Friederich JA, Butterworth JF . Sodium nitroprusside: twenty years and counting. Anesth Analg 1995; 81: 152–162.

    CAS  PubMed  Google Scholar 

  30. Zaiou M, Benachour H, Marteau JB, Visvikis-Siest S, Siest G . Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Curr Pharm Des 2009; 15: 3193–3206.

    Article  CAS  Google Scholar 

  31. Immink RV, van den Born BJ, van Montfrans GA, Kim YS, Hollmann MW, van Lieshout JJ . Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 2008; 52: 236–240.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Grants covering the research: We gratefully acknowledge the financial support of the National High Technology Investigation Project Foundation of China (2008AA02Z433), the National Natural Science Foundation of China (20975021,20805006) and the Major Program Foundation of Fujian Medical University (09ZD013).

Author information

Authors and Affiliations

  1. Department of Anesthesiology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

    K Zeng & C-z Lin

  2. Department of Anesthesiology, Fujian Provincial Hospital, Fuzhou, China

    X-d Wu

  3. Department of Laboratory Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

    Q-c Liu

  4. Department of Gene Diagnosis, Fujian Medical University, Fuzhou, China

    Q-c Liu

  5. Department of Pathology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

    F Gao

Authors
  1. K Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X-d Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Q-c Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C-z Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C-z Lin.

Ethics declarations

Competing interests

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. The manuscript has been submitted solely to this journal and is not published, in press, or submitted elsewhere. The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zeng, K., Wu, Xd., Liu, Qc. et al. Impact of a novel mutation in the 5′-flanking region of natriuretic peptide precursor B gene on the antihypertensive effects of sodium nitroprusside in patients with hypertension. J Hum Hypertens 27, 271–276 (2013). https://doi.org/10.1038/jhh.2012.25

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2012.25

Keywords

Search

Advanced search

Quick links